Bariatric surgery leads to long term lower urinary tract symptoms (LUTS) improvement in male patients with severe obesity: 5-year results from a prospective within-subject cohort study
Abstract
BACKGROUND
Obesity is a known risk factor for lower urinary tract symptoms (LUTS). Current literature has not described the long-term effect of bariatric surgery on male LUTS.
OBJECTIVES
To investigate the 5-year long-term follow-up data on the effect of bariatric surgery on LUTS improvement in male patients with severe obesity.
SETTING
University Hospital, Hong Kong.
METHODS
This is a prospective cohort study. All consecutive male patients from 2010-2020 undergoing bariatric surgery were recruited, with prospective collection of preoperative and postoperative International Prostate Symptom Score (IPSS), anthropometric measurements, metabolic syndrome parameters, and blood parameters. Within-subject analysis was performed to compare the changes in IPSS over time.
RESULTS
One hundred seventy-three male patients were included. There was statistically significant IPSS total symptom score improvement up to 4 years after bariatric surgery in all patients (6.87 versus 5.63, P = .037) and up to 5 years in patients with moderate-to-severe baseline LUTS (13.53 versus 10.03, P = .001). The quality-of-life score was statistically significantly improved up to 5 years. Both voiding and storage symptom showed statistically significant improvement. Univariate and multivariable logistic regression showed percentage change in waist circumference to be a significant predictor of a clinically significant IPSS improvement of 3 or more.
CONCLUSIONS
This is the largest cohort with the longest…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.
Read the paper
Related studies
- Luteolin rescues postmenopausal osteoporosis elicited by OVX through alleviating osteoblast pyroptosis via activating PI3K-AKT signaling
- Drugs Used in “Chemsex”/Sexualized Drug Behaviour—Overview of the Related Clinical Psychopharmacological Issues
- Luteolin Inhibits Dexamethasone‐Induced Osteoporosis by Autophagy Activation Through miR‐125b‐5p/SIRT3/AMPK/mTOR Axis, an In Vitro and In Vivo Study
- Cutting-edge insights into liver fibrosis: advanced therapeutic strategies and future perspectives using engineered mesenchymal stem cell-derived exosomes
- Can we predict and manage persistent storage and voiding LUTS following bladder outflow resistance reduction surgery in men? ICI‐RS 2023
- Chylomicron-mimicking supramolecular nano emulsion for oral luteolin delivery against hyperuricemia
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.